Erasca, Inc. Cash Flow Statement
ERAS / Health Care|5 years of annual SEC 10-K data (FY2020-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
Erasca, Inc. used $109M in operating cash flow and negative free cash flow of $109M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Net Income | -$161.7M | -$125.0M | -$242.8M | -$122.8M | -$101.7M |
| Depreciation & Amortization | $3.8M | $3.7M | $2.6M | $829.0K | $540.0K |
| Operating Cash Flow | -$109.4M | -$101.2M | -$103.3M | -$79.6M | -$32.7M |
| Capital Expenditures | $60.0K | $1.8M | $14.6M | $11.2M | $947.0K |
| Free Cash Flow | -$109.5M | -$103.0M | -$117.8M | -$90.8M | -$33.6M |